CL2015001147A1 - Terapia adyuvante con inhibidores de quinasa de la familia tec - Google Patents

Terapia adyuvante con inhibidores de quinasa de la familia tec

Info

Publication number
CL2015001147A1
CL2015001147A1 CL2015001147A CL2015001147A CL2015001147A1 CL 2015001147 A1 CL2015001147 A1 CL 2015001147A1 CL 2015001147 A CL2015001147 A CL 2015001147A CL 2015001147 A CL2015001147 A CL 2015001147A CL 2015001147 A1 CL2015001147 A1 CL 2015001147A1
Authority
CL
Chile
Prior art keywords
kinase inhibitors
adjuvant therapy
tec family
tec
family
Prior art date
Application number
CL2015001147A
Other languages
English (en)
Spanish (es)
Inventor
Joseph J Buggy
Tarak Mody
Richard B Love
John C Byrd
Betty Chang
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of CL2015001147A1 publication Critical patent/CL2015001147A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CL2015001147A 2012-11-02 2015-04-30 Terapia adyuvante con inhibidores de quinasa de la familia tec CL2015001147A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722107P 2012-11-02 2012-11-02
US201361785868P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2015001147A1 true CL2015001147A1 (es) 2015-06-26

Family

ID=50628113

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001147A CL2015001147A1 (es) 2012-11-02 2015-04-30 Terapia adyuvante con inhibidores de quinasa de la familia tec

Country Status (22)

Country Link
US (4) US9717731B2 (OSRAM)
EP (1) EP2914263A4 (OSRAM)
JP (3) JP2015536950A (OSRAM)
KR (1) KR20150080592A (OSRAM)
CN (2) CN104994858A (OSRAM)
AU (3) AU2013337663A1 (OSRAM)
BR (1) BR112015010059A2 (OSRAM)
CA (1) CA2890111A1 (OSRAM)
CL (1) CL2015001147A1 (OSRAM)
CR (1) CR20150242A (OSRAM)
DO (1) DOP2015000098A (OSRAM)
EA (1) EA201590822A1 (OSRAM)
HK (1) HK1214508A1 (OSRAM)
IL (1) IL238548A0 (OSRAM)
MX (2) MX2015005633A (OSRAM)
NI (1) NI201500062A (OSRAM)
PE (1) PE20151604A1 (OSRAM)
PH (1) PH12015500985A1 (OSRAM)
SG (1) SG11201503459SA (OSRAM)
TN (1) TN2015000170A1 (OSRAM)
TW (1) TW201427664A (OSRAM)
WO (1) WO2014071231A1 (OSRAM)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
ES2794006T3 (es) 2010-10-26 2020-11-17 Mars Inc Inhibidores de arginasa como agentes terapéuticos
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2815858C (en) 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
RU2711077C9 (ru) 2012-03-15 2020-08-11 Селджен Кар Ллс Соли ингибитора киназы рецептора эпидермального фактора роста
WO2014018567A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
AR097204A1 (es) * 2013-08-02 2016-02-24 Pharmacyclics Inc Métodos de tratamiento de tumores sólidos
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
TWI660739B (zh) * 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
US10314842B2 (en) * 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2015187848A1 (en) * 2014-06-04 2015-12-10 Sampath Deepa Hdac inhibitor and btk inhibitor combinations
US20150361504A1 (en) * 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
CA2954725A1 (en) * 2014-07-25 2016-01-28 Northeastern University Biopolymer-nanoparticle composite implant for tumor cell tracking
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
WO2016044774A1 (en) * 2014-09-18 2016-03-24 Pharmacyclics Llc Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
US20180098972A1 (en) 2015-01-26 2018-04-12 Children's Medical Center Corporation Treatment of infectious diseases
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016138542A1 (en) * 2015-02-28 2016-09-01 Cyprus Therapeutics, Inc. Methods for inhibiting tumors and drug resistance
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
DK3285768T3 (da) 2015-04-21 2021-01-25 Eiger Biopharmaceuticals Inc Farmaceutiske sammensætninger omfattende lonafarnib og ritonavir
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3302485B1 (en) 2015-05-29 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
US20170027941A1 (en) * 2015-07-31 2017-02-02 Pharmacyclics Llc Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
US20170042896A1 (en) * 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
PL3368541T3 (pl) * 2015-10-30 2020-11-02 Calithera Biosciences, Inc. Kompozycje i sposoby hamowania aktywności arginazy
CN108367006B (zh) 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
ES2874592T3 (es) * 2016-02-19 2021-11-05 Eiger Biopharmaceuticals Inc Tratamiento de la infección por el virus de la hepatitis delta con interferón lambda
WO2018005849A1 (en) 2016-06-29 2018-01-04 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CN106405086A (zh) * 2016-09-21 2017-02-15 四川大学华西医院 一种肺癌筛查试剂盒
WO2018085731A2 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
PL3559009T3 (pl) 2016-12-22 2021-10-25 Calithera Biosciences, Inc. Kompozycje i sposoby hamowania aktywności arginazy
CN108732280B (zh) * 2017-04-18 2022-07-08 广东东阳光药业有限公司 一种分离检测盐酸达卡他韦及其光学异构体的方法
WO2019014684A1 (en) * 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
EP3688007B1 (en) 2017-09-27 2024-07-31 The University of York Bioconjugation of polypeptides
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
JP7324778B2 (ja) 2018-05-04 2023-08-10 ポートラ ファーマシューティカルズ， エルエルシー セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
CN111110685A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 一种含伊布替尼的药物组合物及其应用
KR20220061149A (ko) * 2019-09-09 2022-05-12 더 칠드런스 호스피탈 오브 필라델피아 Clec16A 기능장애 또는 손실과 관련된 장애의 치료를 위한 조성물 및 방법
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
US20220378025A1 (en) * 2019-11-11 2022-12-01 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
BR112022014149A2 (pt) 2020-01-22 2022-09-27 Principia Biopharma Inc Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)-1h-pirazolo[3,4-d]pirimidina-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrila
WO2021207716A2 (en) * 2020-04-10 2021-10-14 Ohio State Innovation Foundation Methods and composition for treatment of covid-19 illness requiring hospitalization
WO2021252494A1 (en) * 2020-06-08 2021-12-16 Icahn School Of Medicine At Mount Sinai Use of multi-kinase inhibitors to treat rna virus infections
KR20240169633A (ko) * 2022-04-05 2024-12-03 코버스 파마슈티칼스, 인크. Th1 세포 활성을 증가시키기 위한 itk 저해제
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2025071560A1 (en) * 2023-09-28 2025-04-03 Rutgers, The State University Of New Jersey Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof
WO2024206869A2 (en) * 2023-03-30 2024-10-03 Board Of Regents, The University Of Texas System Combination of hpk1 inhibitor and axl inhibitor in cancer therapy
WO2025085889A1 (en) * 2023-10-20 2025-04-24 Corvus Pharmaceuticals, Inc. Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1240899A3 (en) 1996-01-23 2004-05-19 Ribapharm, Inc. Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
EP1302474A1 (en) 1996-10-16 2003-04-16 Ribapharm, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
CA2345722A1 (en) 1998-09-28 2000-04-06 Albert Edge Determining resistance to treatment for hepatitis c virus
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
AU4463300A (en) 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
WO2001032210A2 (en) 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
JP2003525907A (ja) 2000-03-09 2003-09-02 シェーリング コーポレイション Ｈｉｖ免疫アジュバント治療
WO2001088199A2 (en) 2000-05-18 2001-11-22 Genetics Institute, Llc Identification and modulationof of a t helper-1 and t helper-2 cells
CN1516599A (zh) 2000-10-18 2004-07-28 ���鹫˾ 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
EP1553982A4 (en) 2002-07-15 2008-03-26 Wyeth Corp METHOD AND COMPOSITIONS FOR MODULATING THE DEVELOPMENT AND FUNCTION OF T-HELPER CELLS (T sb H / sb)
EP2572714A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
WO2004110245A2 (en) 2003-05-16 2004-12-23 Intermune, Inc. Combination therapy for cancer treatment
CA2539702A1 (en) 2003-09-30 2005-04-07 Telethon Institute For Child Health Research Immunotherapy method
PT1951300E (pt) 2005-11-04 2011-09-05 Novartis Vaccines & Diagnostic Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
WO2007059329A2 (en) 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
CA2666814A1 (en) 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
AU2008321016B2 (en) 2007-11-12 2013-03-28 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
CN105363034A (zh) 2008-05-23 2016-03-02 香港大学 治疗流感的联合疗法
EP2318031A4 (en) 2008-06-03 2012-09-12 Aethlon Medical Inc IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
WO2010034670A2 (en) 2008-09-26 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
EP2379745A1 (en) 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Biomarkers for hcv treatment response
WO2010093843A2 (en) 2009-02-12 2010-08-19 Vertex Pharmaceuticals Incorporated Hcv combination therapies
SG175289A1 (en) 2009-04-20 2011-11-28 Genentech Inc Adjuvant cancer therapy
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EA201890869A3 (ru) * 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
GB2481611A (en) 2010-06-30 2012-01-04 Statoil Asa Test cell for well fluid assessment
JP2014505666A (ja) * 2010-11-18 2014-03-06 ザ ジェネラル ホスピタル コーポレイション 癌治療のための降圧剤の組成物および使用
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
EP2788020A4 (en) 2011-12-05 2015-04-29 Immunomedics Inc THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
CA3218491A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
CA2890111A1 (en) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Tec family kinase inhibitor adjuvant therapy

Also Published As

Publication number Publication date
SG11201503459SA (en) 2015-06-29
MX2021003018A (es) 2021-05-27
EA201590822A1 (ru) 2016-01-29
US9717731B2 (en) 2017-08-01
WO2014071231A1 (en) 2014-05-08
US20200147084A1 (en) 2020-05-14
CR20150242A (es) 2015-08-17
MX2015005633A (es) 2016-02-03
IL238548A0 (en) 2015-06-30
JP2015536950A (ja) 2015-12-24
EP2914263A1 (en) 2015-09-09
US20140371241A1 (en) 2014-12-18
US20180071293A1 (en) 2018-03-15
EP2914263A4 (en) 2016-04-27
BR112015010059A2 (pt) 2017-07-11
AU2020220205A1 (en) 2020-09-10
TW201427664A (zh) 2014-07-16
TN2015000170A1 (en) 2016-10-03
PE20151604A1 (es) 2015-11-04
CN111329989A (zh) 2020-06-26
DOP2015000098A (es) 2015-06-30
KR20150080592A (ko) 2015-07-09
CN104994858A (zh) 2015-10-21
JP2020183413A (ja) 2020-11-12
CA2890111A1 (en) 2014-05-08
NI201500062A (es) 2016-02-16
AU2018233032B2 (en) 2020-05-21
US20140134265A1 (en) 2014-05-15
AU2013337663A1 (en) 2015-06-11
PH12015500985A1 (en) 2015-08-03
AU2018233032A1 (en) 2018-10-11
JP2019031506A (ja) 2019-02-28
HK1214508A1 (zh) 2016-07-29

Similar Documents

Publication Publication Date Title
CL2015001147A1 (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
IL265007B (en) Pyrazolopyrimidine compounds as kinase inhibitors
DK3321262T3 (da) Serin-/threoninkinasehæmmere
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
EP3027604A4 (en) NOVEL CHINAZOLINONE AS BROMDOMANENHEMMER
ZA201502783B (en) Azaquinazoline inhibitors of atypical protein kinase c
SI3513806T1 (sl) Sestava imunogena
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
BR112015005361A2 (pt) inibidores de tirosina quinase de bruton
EP3083559A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP2880038A4 (en) PROTEIN KINASE INHIBITORS
ZA201604461B (en) Serine/threonine kinase inhibitors
EP2879679A4 (en) ANTIBACTERIAL PROTEIN KINASE INHIBITORS
EP3082807A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560A4 (en) Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
ITRM20120473A1 (it) Use of glycerophosphoinositols for the treatment of septic shock
ITMI20130605A1 (it) Procedimento per la preparazione di composti benzoeterodiazolici disostituiti con gruppi benzoditiofenici
EP2841339A4 (en) REDUNDANT MOUNTING OF A TEC MOUNT
FI20126161L (fi) Seinän pintakäsittely
GB201323021D0 (en) Use of kinase inhibitors
TWM475181U (en) Structure of shoesole
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
UA25008S (uk) Набір меблів
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors